BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Tuesday, March 19, 2024
See today's BioWorld
Home
» Akebia blossoms: IPO upsized, raises $100M for CKD anemia effort
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Akebia blossoms: IPO upsized, raises $100M for CKD anemia effort
March 21, 2014
By
Randy Osborne
No Comments
Akebia Therapeutics Inc. beat the target amount raised in its initial public offering to raise about $100 million, and started off trading with a bang, closing Thursday (NASDAQ:AKBA) at $26.70, up 57 percent.
BioWorld